Discontinuation and restarting in patients on statin therapy: a cohort study using a primary care database

Objectives: To estimate rates of discontinuation and restarting of statins, and to identify patient characteristics associated with either discontinuation or restarting. Design: Prospective open cohort study. Setting: 664 general practices contributing to the Clinical Practice Research Datali...

Full description

Bibliographic Details
Main Authors: Vinogradova, Yana, Coupland, Carol, Brindle, Peter, Hippisley-Cox, Julia
Format: Article
Published: BMJ Publishing Group 2016
Subjects:
Online Access:https://eprints.nottingham.ac.uk/34505/
_version_ 1848794870511042560
author Vinogradova, Yana
Coupland, Carol
Brindle, Peter
Hippisley-Cox, Julia
author_facet Vinogradova, Yana
Coupland, Carol
Brindle, Peter
Hippisley-Cox, Julia
author_sort Vinogradova, Yana
building Nottingham Research Data Repository
collection Online Access
description Objectives: To estimate rates of discontinuation and restarting of statins, and to identify patient characteristics associated with either discontinuation or restarting. Design: Prospective open cohort study. Setting: 664 general practices contributing to the Clinical Practice Research Datalink in the United Kingdom. Data extracted in October 2014. Participants: Incident statin users aged 25-84 years identified between January 2002 and September 2013. Patients with statin prescriptions divided into two groups: primary prevention and secondary prevention (those already diagnosed with cardiovascular disease). Patients with statin prescriptions in the 12 months before study entry were excluded. Main outcome measures: Discontinuation of statin treatment (first 90 day gap after the estimated end date of a statin prescription), and restarting statin treatment for those who discontinued (defined as any subsequent prescription between discontinuation and study end). Results: Of 431 023 patients prescribed statins as primary prevention with a median follow-up time of 137 weeks, 47% (n=204 622) discontinued treatment and 72% (n=147 305) of those who discontinued restarted. Of 139 314 patients prescribed statins as secondary prevention with median follow-up time of 182 weeks, 41% (n=57 791) discontinued treatment and 75% (43 211) of those who discontinued restarted. Younger patients (aged ≤50 years), older patients (≥75 years), women, and patients with chronic liver disease were more likely to discontinue statins and less likely to restart. However, patients in ethnic minority groups, current smokers, and patients with type 1 diabetes were more likely to discontinue treatment but then were more likely to restart, whereas patients with hypertension and type 2 diabetes were less likely to discontinue treatment and more likely to restart if they did discontinue. These results were mainly consistent in the primary prevention and secondary prevention groups. Conclusions: Although a large proportion of statin users discontinue, many of them restart. For many patient groups previously considered as “stoppers,” the problem of statin treatment “stopping” could be part of the wider issue of poor adherence. Identification of patient groups associated with completely stopping or stop-starting behaviour has positive implications for patients and doctors as well as suggesting areas for future research.
first_indexed 2025-11-14T19:23:04Z
format Article
id nottingham-34505
institution University of Nottingham Malaysia Campus
institution_category Local University
last_indexed 2025-11-14T19:23:04Z
publishDate 2016
publisher BMJ Publishing Group
recordtype eprints
repository_type Digital Repository
spelling nottingham-345052020-05-04T17:54:56Z https://eprints.nottingham.ac.uk/34505/ Discontinuation and restarting in patients on statin therapy: a cohort study using a primary care database Vinogradova, Yana Coupland, Carol Brindle, Peter Hippisley-Cox, Julia Objectives: To estimate rates of discontinuation and restarting of statins, and to identify patient characteristics associated with either discontinuation or restarting. Design: Prospective open cohort study. Setting: 664 general practices contributing to the Clinical Practice Research Datalink in the United Kingdom. Data extracted in October 2014. Participants: Incident statin users aged 25-84 years identified between January 2002 and September 2013. Patients with statin prescriptions divided into two groups: primary prevention and secondary prevention (those already diagnosed with cardiovascular disease). Patients with statin prescriptions in the 12 months before study entry were excluded. Main outcome measures: Discontinuation of statin treatment (first 90 day gap after the estimated end date of a statin prescription), and restarting statin treatment for those who discontinued (defined as any subsequent prescription between discontinuation and study end). Results: Of 431 023 patients prescribed statins as primary prevention with a median follow-up time of 137 weeks, 47% (n=204 622) discontinued treatment and 72% (n=147 305) of those who discontinued restarted. Of 139 314 patients prescribed statins as secondary prevention with median follow-up time of 182 weeks, 41% (n=57 791) discontinued treatment and 75% (43 211) of those who discontinued restarted. Younger patients (aged ≤50 years), older patients (≥75 years), women, and patients with chronic liver disease were more likely to discontinue statins and less likely to restart. However, patients in ethnic minority groups, current smokers, and patients with type 1 diabetes were more likely to discontinue treatment but then were more likely to restart, whereas patients with hypertension and type 2 diabetes were less likely to discontinue treatment and more likely to restart if they did discontinue. These results were mainly consistent in the primary prevention and secondary prevention groups. Conclusions: Although a large proportion of statin users discontinue, many of them restart. For many patient groups previously considered as “stoppers,” the problem of statin treatment “stopping” could be part of the wider issue of poor adherence. Identification of patient groups associated with completely stopping or stop-starting behaviour has positive implications for patients and doctors as well as suggesting areas for future research. BMJ Publishing Group 2016-06-28 Article PeerReviewed Vinogradova, Yana, Coupland, Carol, Brindle, Peter and Hippisley-Cox, Julia (2016) Discontinuation and restarting in patients on statin therapy: a cohort study using a primary care database. BMJ, 353 . i3305. ISSN 1756-1833 statin treatment; primary care; database http://www.bmj.com/content/353/bmj.i3305 doi: http://dx.doi.org/10.1136/bmj.i3305 doi: http://dx.doi.org/10.1136/bmj.i3305
spellingShingle statin treatment; primary care; database
Vinogradova, Yana
Coupland, Carol
Brindle, Peter
Hippisley-Cox, Julia
Discontinuation and restarting in patients on statin therapy: a cohort study using a primary care database
title Discontinuation and restarting in patients on statin therapy: a cohort study using a primary care database
title_full Discontinuation and restarting in patients on statin therapy: a cohort study using a primary care database
title_fullStr Discontinuation and restarting in patients on statin therapy: a cohort study using a primary care database
title_full_unstemmed Discontinuation and restarting in patients on statin therapy: a cohort study using a primary care database
title_short Discontinuation and restarting in patients on statin therapy: a cohort study using a primary care database
title_sort discontinuation and restarting in patients on statin therapy: a cohort study using a primary care database
topic statin treatment; primary care; database
url https://eprints.nottingham.ac.uk/34505/
https://eprints.nottingham.ac.uk/34505/
https://eprints.nottingham.ac.uk/34505/